Think You Know What AI Does Next?

Which model leads the next benchmark? Which AI lab ships the next major breakthrough?

Kalshi lets you trade on real-world AI and technology events as the industry moves. If you follow launches, model updates, and benchmarks closely, put that knowledge to work.

Bonus credit varies from $15 to $500. Terms apply.

THE WEEK OF JULY 13, 2026

GET READY…

Tech companies are readying Q2 earnings reports — and we’re ready to refute the notion of a bubble. We expect these reports will too.

Meanwhile, the race to create new large language models is coming hot and heavy, with weighting as a central issue. This will surely be a distinguishing factor and an issue in the Anthropic IPO, as the company argues for “safety” while Chinese competitors offer more control. When will we see that S-1?

Have you seen our new website and our new searchable research database at https://epistrophy.beehiiv.com?!? Check it out!

LET’S GO 👇

Table of Contents

TWEET OF THE WEEK

EPISTROPHY IN THE NEWS 🗞️

NewsNation’s Alicia Nieves took on the tough topic of propaganda from China, Iran and Russia seeking to inflame the already-raging debate of AI Data Centers. I took the tack that the debate is real, but the inflaming doesn’t have to happen.

The unlock for agentic workflows may turn out to be an unglamorous one: cross-border payments. That's the thread I picked up in Aaron Ricadela's new eBook, "Battle Is On for $2.5 Trillion Cross-Border Payments Market," where I argued that moving money across borders becomes a serious accelerant the moment agents start transacting on their own behalf. The conversation pulled me straight back to my fintech days at Ripple and Braintrust, when "settle it instantly, anywhere" was the whole ballgame — and payments and agents were nowhere near colliding the way they are now.

Bubble or no Bubble? The signal everyone's watching for the AI top — spare compute changing hands — is the wrong one. Asked by the InvestorsObserver newsletter what would first warn that AI spending is cooling, I pushed back on reading deals like xAI renting idle capacity to Anthropic as the beginning of the end: that's not the buildout cracking, it's a verdict on Grok, and the freed-up capacity is exactly what hands a challenger like Cursor its shot. The real tell is the day AI usage flattens — and we're nowhere near it.

AVAILABILITY NEXT WEEK

On Wednesday afternoon last week San Francisco recored the coldest temperature in America (60º F at SFO) — so why would I leave? I’ll be in our San Francisco office all week so text or call and I’ll do my best to captivate you on this amazing moment in technology.

Written reports are available to clients, our IPO reports for $5,000. Video summaries on YouTube, and of course our popular summaries of the summaries on Instagram, TikTok, and YouTube Shorts.

THE WEEK AHEAD 📆

TICKER

NAME

MARKET CAP

DATE

TYPE

CPI

Consumer Price Index

Jul 14

Economic Event

ASML

ASML Holding NV

$707 B

Jul 15

Earnings

PPI

Producer Price Index

Jul 15

Economic Event

NFLX

Netflix

$309 B

Jul 16

Earnings

RS

Advance Retail & Food Services Sales

Jul 16

Economic Event

IP

Industrial Production & Capacity Utilization

Jul 17

Economic Event

NHC

New Residential Construction

Jul 17

Economic Event

IBM

IBM Common Stock

$270 B

Jul 22

Earnings

AMD

AMD Advancing AI

$910 B

Jul 22

Conference

SAP

SAP SE

$192 B

Jul 23

Earnings

NOK

Nokia Oyj

$71 B

Jul 23

Earnings

NRS

New Residential Sales

Jul 24

Economic Event

SNPS

Design Automation Conference 2026

$85 B

Jul 25

Conference

We certify that (1) the views expressed in this report accurately reflect our views about all of the subject companies and securities and (2) no part of my compensation was, is or will be directly related to the specific recommendations or views expressed in this report.

Important disclosures

Important disclosures are available by calling (347) 619-2489 or writing to Epistrophy Capital Research, One Ferry Building, Suite 201, San Francisco, CA 94105.

Epistrophy Capital Research is an independent research provider and does not operate as a financial institution. Epistrophy explicitly does not provide investment advice, stock recommendations, or solicitations to buy or sell any securities.

The research reports provided by Epistrophy Capital Research contain opinions derived from publicly available information, issuer communications, recognized statistical services, and other reputable sources considered reliable. However, Epistrophy does not independently verify the accuracy or completeness of such information and explicitly disclaims responsibility for any errors or omissions.

Opinions and analysis contained within Epistrophy's research reports are current only at the time of publication and are subject to change without notice. Readers must independently verify facts and conduct their own due diligence before making investment decisions.

Epistrophy Capital Research does not consider or evaluate individual investor circumstances, including investment objectives, financial situations, or risk tolerance. Investing in securities, particularly small-cap and micro-cap stocks, involves substantial risks, including significant volatility and potential loss of principal. Readers are strongly advised to consult their financial advisor or another qualified professional before acting on any information provided. Readers should assume Epistrophy Capital Research, its principals or its contributors may have positions, long or short, any of the companies discussed and the Epistrophy Capital Research principals or contributors may have had or currently have business interests in the companies discussed.

Past performance referenced in Epistrophy reports is not indicative of future results. Security prices can fluctuate widely, and investors should be aware that investments can result in significant financial losses. Epistrophy Capital Research or its Unless explicitly stated otherwise, prices quoted in reports reflect market closing prices from the previous trading day.

Epistrophy Capital Research publications are intended solely for direct recipients and should not be redistributed or shared with third parties without explicit permission from Epistrophy Capital Research LLC.

Epistrophy Capital Research reports are provided strictly for informational purposes and do not constitute a comprehensive analysis of any company, security, or industry. No content within these reports should be considered accounting, tax, legal, or professional advice.

Links or references to third-party websites or external resources are provided solely for informational convenience. Epistrophy Capital Research expressly disclaims endorsement of, and responsibility for, the content, accuracy, or reliability of such external information. Accessing third-party information is done entirely at the user's own risk.

For additional details, clarification, or specific inquiries regarding Epistrophy Capital Research reports, please contact Epistrophy Capital Research LLC directly.

Reply

Avatar

or to participate